Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...

Inflammatory Bowel Disease III: Crohn's Disease

Inflammatory Bowel Disease III: Crohn's Disease

Crohn’s disease is a chronic, relapsing form of inflammatory bowel disease characterized by segmental, transmural inflammation that can affect any part of the gastrointestinal tract. Its pathogenesis arises from a combination of genetic susceptibility, environmental exposures, epithelial barrier dysfunction, and immune dysregulation. Together, these factors lead to an exaggerated immune response against components of the gut microbiome.Genetic and Environmental InfluencesMultiple genetic...

Inflammatory Bowel Disease II: Crohn's Disease

Inflammatory Bowel Disease II: Crohn's Disease

Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by transmural...

Inflammatory Bowel Disease IV: Pharmacological Management

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Performance of the permutation test approach with base calling errors for detecting changes in variant allele frequencies in ctDNA for a single patient.

Statistical applications in genetics and molecular biology·2026

Same author

BAP1 and USP1 cooperate to regulate FANCD2 stability and cell proliferation in mesothelioma cells.

Cell death & disease·2026

Same author

Temporal trends and regional variations in hepatocellular carcinoma etiology: a multinational study across Asia.

Hepatology international·2026

Same author

Endoscopic ultrasonography-guided B3 branch drainage/anastomosis as hepaticoduodenostomy in atrophic left hepatic lobe case.

Endoscopy·2026

Same author

Effect of Direct-Acting Antivirals on Prognosis in Older Patients With Hepatitis C Virus-Related Hepatocellular Carcinoma After Curative Therapy: A Retrospective Study by the Red Cross Liver Study Group in Japan.

Hepatology research : the official journal of the Japan Society of Hepatology·2026

Same author

Sofosbuvir/Velpatasvir in Chronic Hepatitis C, Compensated and Decompensated Cirrhosis, and Retreatment Settings.

Internal medicine (Tokyo, Japan)·2026

Search research articles

Related Experiment Video

Updated: Jun 25, 2026

Du-Moxibustion in a Mouse Model of Ankylosing Spondylitis

Du-Moxibustion in a Mouse Model of Ankylosing Spondylitis

Published on: October 27, 2023

[Two cases with ankylosing spondylitis using infliximab (case report)].

Jo Nishino¹, Kenichi Kato, Hideo Yoshida

¹Division of Rheumatology and Infectious Diseases, Department of Internal Medicine, Fujita Health University School of Medicine.

Nihon Rinsho Men'Eki Gakkai Kaishi = Japanese Journal of Clinical Immunology

|March 3, 2009

Summary

Infliximab (IFX) offers a new treatment option for ankylosing spondylitis (AS) that does not respond to traditional therapies. This biologic agent effectively reduced pain and inflammation in patients with refractory AS.

Related Experiment Videos

Last Updated: Jun 25, 2026

Du-Moxibustion in a Mouse Model of Ankylosing Spondylitis

Du-Moxibustion in a Mouse Model of Ankylosing Spondylitis

Published on: October 27, 2023

Area of Science:

Rheumatology
Immunology

Background:

Ankylosing spondylitis (AS) is a chronic inflammatory disease primarily affecting the axial skeleton.
Conventional treatments include NSAIDs, sulfasalazine, methotrexate, and corticosteroids, but some patients exhibit refractory disease.

Observation:

Two male patients diagnosed with AS experienced persistent symptoms despite conventional therapies.
Case 1: A 46-year-old man with AS refractory to NSAIDs, sulfasalazine, methotrexate, and prednisolone.
Case 2: A 57-year-old man with AS refractory to NSAIDs, prednisolone, bucillamine, methotrexate, and leflunomide.

Findings:

Infliximab (IFX) administration led to significant improvement in pain and inflammatory markers in both patients.
Concomitant medications were reduced or discontinued following IFX initiation.
IFX demonstrated efficacy in managing refractory AS symptoms, including joint pain and swelling.

Implications:

Infliximab (IFX) represents a viable therapeutic option for patients with ankylosing spondylitis resistant to standard treatments.
This case study highlights the potential of biologic agents in managing severe, refractory AS.
Further research into the long-term efficacy and safety of IFX in AS is warranted.